A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori

Vaccine

Volumn 29, Issue 6, 2011, Pages 1235-1241

  Flach, Carl Fredrik ^a   Svensson, Natascha ^a   Blomquist, Margareta ^a   Ekman, Annelie ^a   Raghavan, Sukanya ^a   Holmgren, Jan ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Helicobacter pylori; HpaA; Vaccine

Indexed keywords

BACTERIAL ANTIGEN; DETERGENT; HELICOBACTER PYLORI ANTIGEN UREB; HELICOBACTER PYLORI VACCINE; INTERLEUKIN 17; LIPOPROTEIN; LIPOPROTEIN HPAA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG POTENTIATION; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH; STOMACH MUCOSA;

ADHESINS, BACTERIAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTOCYTOCHEMISTRY; LYMPH NODES; LYMPHOCYTES; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; STOMACH; VACCINES, SYNTHETIC;

EID: 78751579061     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.088     Document Type: Article

References (46)

1. Kusters J.G., van Vliet A.H., Kuipers E.J. Pathogenesis of Helicobacter pylori infection. Clinical Microbiology Reviews 2006, 19(July (3)):449-490.
2. McNamara D., El-Omar E. Helicobacter pylori infection and the pathogenesis of gastric cancer: a paradigm for host-bacterial interactions. Digestive and Liver Disease 2008, 40(July (7)):504-509.
3. Niv Y., Hazazi R. Helicobacter pylori recurrence in developed and developing countries: meta-analysis of 13C-urea breath test follow-up after eradication. Helicobacter 2008, 13(February (1)):56-61.
4. Corthesy-Theulaz I., Porta N., Glauser M., Saraga E., Vaney A.C., Haas R., et al. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology 1995, 109(July (1)):115-121.
5. Michetti P., Corthesy-Theulaz I., Davin C., Haas R., Vaney A.C., Heitz M., et al. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology 1994, 107(October (4)):1002-1011.
6. Ghiara P., Rossi M., Marchetti M., Di Tommaso A., Vindigni C., Ciampolini F., et al. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infection and immunity 1997, 65(December (12)):4996-5002.
7. Satin B., Del Giudice G., Della Bianca V., Dusi S., Laudanna C., Tonello F., et al. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. The Journal of Experimental Medicine 2000, 191(May (9)):1467-1476.
8. Radcliff F.J., Hazell S.L., Kolesnikow T., Doidge C., Lee A Catalase, a novel antigen for Helicobacter pylori vaccination. Infection and Immunity 1997, 65(November (11)):4668-4674.
9. Nystrom J., Raghavan S., Svennerholm A.M. Mucosal immune responses are related to reduction of bacterial colonization in the stomach after therapeutic Helicobacter pylori immunization in mice. Microbes and infection/Institut Pasteur 2006, 8(February (2)):442-449.
10. Lundstrom A.M., Blom K., Sundaeus V., Bolin I. HpaA shows variable surface localization but the gene expression is similar in different Helicobacter pylori strains. Microbial Pathogenesis 2001, 31(November (5)):243-253.
11. O'Toole P.W., Janzon L., Doig P., Huang J., Kostrzynska M., Trust T.J. The putative neuraminyllactose-binding hemagglutinin HpaA of Helicobacter pylori CCUG 17874 is a lipoprotein. Journal of Bacteriology 1995, 177(November (21)):6049-6057.
12. Bolin I., Lonroth H., Svennerholm A.M. Identification of Helicobacter pylori by immunological dot blot method based on reaction of a species-specific monoclonal antibody with a surface-exposed protein. Journal of Clinical Microbiology 1995, 33(February (2)):381-384.
13. Yan J., Mao Y.F., Shao Z.X. Frequencies of the expression of main protein antigens from Helicobacter pylori isolates and production of specific serum antibodies in infected patients. World Journal of Gastroenterology 2005, 11(January (3)):421-425.
14. Alm R.A., Ling L.S., Moir D.T., King B.L., Brown E.D., Doig P.C., et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 1999, 397(January (6715)):176-180.
15. Tomb J.F., White O., Kerlavage A.R., Clayton R.A., Sutton G.G., Fleischmann R.D., et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997, 388(August (6642)):539-547.
16. Carlsohn E., Nystrom J., Bolin I., Nilsson C.L., Svennerholm A.M. HpaA is essential for Helicobacter pylori colonization in mice. Infection and Immunity 2006, 74(February (2)):920-926.
17. Mattsson A., Tinnert A., Hamlet A., Lonroth H., Bolin I., Svennerholm A.M. Specific antibodies in sera and gastric aspirates of symptomatic and asymptomatic Helicobacter pylori-infected subjects. Clinical and Diagnostic Laboratory Immunology 1998, 5(May (3)):288-293.
18. Sutton P., Doidge C., Pinczower G., Wilson J., Harbour S., Swierczak A., et al. Effectiveness of vaccination with recombinant HpaA from Helicobacter pylori is influenced by host genetic background. FEMS Immunology and Medical Microbiology 2007, 50(July (2)):213-219.
19. Raghavan S., Svennerholm A.M., Holmgren J. Effects of oral vaccination and immunomodulation by cholera toxin on experimental Helicobacter pylori infection, reinfection, and gastritis. Infection and Immunity 2002, 70(August (8)):4621-4627.
20. Raghavan S., Fredriksson M., Svennerholm A.M., Holmgren J., Suri-Payer E. Absence of CD4+CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice. Clinical and Experimental Immunology 2003, 132(June (3)):393-400.
21. Lindgren A., Pavlovic V., Flach C.F., Sjoling A., Lundin S. Interferon-gamma secretion is induced in IL-12 stimulated human NK cells by recognition of Helicobacter pylori or TLR2 ligands. Innate Immunity 2010, (February). doi:10.1177/1753425909357970, [Epub ahead of print].
22. Weeks D.L., Eskandari S., Scott D.R., Sachs G. A H+-gated urea channel: the link between Helicobacter pylori urease and gastric colonization. Science (New York, NY) 2000, 287(January (5452)):482-485.
23. DeLyria E.S., Redline R.W., Blanchard T.G. Vaccination of mice against H pylori induces a strong Th-17 response and immunity that is neutrophil dependent. Gastroenterology 2009, 136(January (1)):247-256.
24. Ermak T.H., Giannasca P.J., Nichols R., Myers G.A., Nedrud J., Weltzin R., et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. The Journal of Experimental Medicine 1998, 188(December (12)):2277-2288.
25. Velin D., Favre L., Bernasconi E., Bachmann D., Pythoud C., Saiji E., et al. Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. Gastroenterology 2009, 136(June (7)):2237 e1-2246 e1.
26. Cuburu N., Kweon M.N., Hervouet C., Cha H.R., Pang Y.Y., Holmgren J., et al. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. Journal of Immunology 2009, 183(December (12)):7851-7859.
27. Song J.H., Nguyen H.H., Cuburu N., Horimoto T., Ko S.Y., Park S.H., et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(February (5)):1644-1649.
28. Lundstrom A.M., Bolin I., Bystrom M., Nystrom S. Recombinant HpaA purified from Escherichia coli has biological properties similar to those of native Helicobacter pylori HpaA. APMIS 2003, 111(March (3)):389-397.
29. Holmgren J., Adamsson J., Anjuere F., Clemens J., Czerkinsky C., Eriksson K., et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunology letters 2005, 97(March (2)):181-188.
30. Summerton N.A., Welch R.W., Bondoc L., Yang H.H., Pleune B., Ramachandran N., et al. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 2010, 28(February (5)):1404-1411.
31. Östberg A.K., Sjökvist-Ottsjö L., Flach C.F., Clements J., Holmgren J., Raghavan S. Evaluation of adjuvant mechanisms for the development of a vaccine against Helicobacter pylori infection. 9th international workshop on pathogenesis and host response in Helicobacter infections 2010.
32. Kabir S The current status of Helicobacter pylori vaccines: a review. Helicobacter 2007, 12(April (2)):89-102.
33. Gomez-Duarte O.G., Lucas B., Yan Z.X., Panthel K., Haas R., Meyer T.F. Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine 1998, 16(March (5)):460-471.
34. Angelakopoulos H., Hohmann E.L. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infection and Immunity 2000, 68(April (4)):2135-2141.
35. Bumann D., Metzger W.G., Mansouri E., Palme O., Wendland M., Hurwitz R., et al. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2001, 20(December (5-6)):845-852.
36. DiPetrillo M.D., Tibbetts T., Kleanthous H., Killeen K.P., Hohmann E.L. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 1999, 18(October (5-6)):449-459.
37. Aebischer T., Bumann D., Epple H.J., Metzger W., Schneider T., Cherepnev G., et al. Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut 2008, 57(August (8)):1065-1072.
38. Michetti P., Kreiss C., Kotloff K.L., Porta N., Blanco J.L., Bachmann D., et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999, 116(April (4)):804-812.
39. Malfertheiner P., Schultze V., Rosenkranz B., Kaufmann S.H., Ulrichs T., Novicki D., et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 2008, 135(September (3)):787-795.
40. Flach CF, Ostberg AK, Nilsson AT, De Waal Malefyt R, Raghavan S. Pro-inflammatory cytokine gene expression in the stomach correlates with vaccine-induced protection against Helicobacter pylori infection in mice: an important role for interleukin-17 during the effector phase. Infection and Immunity 2011; 79(February (2)).
41. Zhou W.Y., Shi Y., Wu C., Zhang W.J., Mao X.H., Guo G., et al. Therapeutic efficacy of a multi-epitope vaccine against Helicobacter pylori infection in BALB/c mice model. Vaccine 2009, 27(August (36)):5013-5019.
42. Cuburu N., Kweon M.N., Song J.H., Hervouet C., Luci C., Sun J.B., et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 2007, 25(December (51)):8598-8610.
43. Raghavan S., Ostberg A.K., Flach C.F., Ekman A., Blomquist M., Czerkinsky C., et al. Sublingual immunization protects against Helicobacter pylori infection and induces T and B cell responses in the stomach. Infection and Immunity 2010, 78(October (10)):4251-4260.
44. Song J.H., Kim J.I., Kwon H.J., Shim D.H., Parajuli N., Cuburu N., et al. CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination. Journal of Immunology 2009, 182(June (11)):6851-6860.
45. Johansson E.L., Bergquist C., Edebo A., Johansson C., Svennerholm A.M. Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine 2004, 22(February (8)):984-990.
46. van Ginkel F.W., Jackson R.J., Yoshino N., Hagiwara Y., Metzger D.J., Connell T.D., et al. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infection and Immunity 2005, 73(October (10)):6892-6902.